Skip to content
Parakho

Axiscades Technologies LtdQ4 FY26 earnings call

All quarters

Summary generated by AI from the official transcript Axiscades Technologies Ltd filed with BSE on 04 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries

The short read

AXISCADES reported FY26 revenue growth of 12.4% and EBITDA growth of 24.6% with margin expansion to 15.3%, while Q4 results were affected by a revenue recognition deferment, portfolio restructuring costs, and a higher tax base. Management explained that 142 crores of Q4 revenue shifted into FY27 due to supply chain disruptions and a divestment-related transition, and that reported PAT declined 4.3% year-on-year despite operating growth. The company also detailed a divestment of its heavy engineering, energy, and automotive practice to Akkodis, the creation of a new subsidiary called Xida Inc, and capacity investments in Devanahalli and Hyderabad.

Numbers mentioned

Revenue: 1,159 crores (FY26)

p. 5
Revenue was at 1,159 crores (12.4% growth year-on-year)

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

EBITDA: 178 crores (FY26)

p. 5
EBITDA was at 178 crores (24.6% growth year-on-year) with margins at 15.3%, which is 150 bps more than last year

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

PBT before exceptional items: 125 crores (FY26)

p. 5
PBT before exceptional items was 125 crores (36.5% growth year-on-year)

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

PBT after exceptional items: 114 crores (FY26)

p. 5
PBT after exceptional items was 114 crores (29.8% growth year-on-year)

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Normalized PAT: 83 crores (FY26)

p. 5
Normalized PAT came at 83 crores (27.6% growth) versus normalized FY25 PAT of 65 crores

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Reported PAT: 72 crores (FY26)

p. 5
The reported PAT at 72 crores showed a 4.3% degrowth year-on-year, which we will explain

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Reported revenue: 273 crores (Q4 FY26)

p. 5
For Q4 specifically, reported revenue was 273 crores, EBITDA was 34 crores, pre-exceptional PBT was 14 crores, and PAT was at 0.4 crores

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Q4 revenue deferment: 142 crores (Q4 FY26)

p. 5
First, the Q4 revenue recognition shift of 142 crores, which carried an EBITDA impact of more than 40 crores

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Exceptional items: 11.17 crores (FY26)

p. 5
Regarding Factor 2 - exceptional items of 11.17 crores - on May 26th, 2026, AXISCADES signed definitive agreements to divest the heavy engineering, energy, and automotive practice to

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Tax charge: 42 crores (FY26)

p. 6
Regarding the tax charge, FY26 was 42 crores against 12 crores in FY25

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Closing receivables / DSO: 411 crores / 130 days (FY26 close)

p. 6
Regarding the balance sheet, closing receivables were 411 crores with a DSO of 130 days

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Gross borrowings: 276 crores (FY26 close)

p. 6
Gross borrowings increased by 87 crores to 276 crores for project-specific working capital for land systems; this retires as invoices are issued

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Core domain revenue: 904 crores (78% of consolidated revenue) (FY26)

p. 6
the core domains of aerospace, defense, and ESAI generated 904 crores in revenue (78% of consolidated revenue)

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Aerospace revenue: 388 crores (21% growth), 17.3% EBITDA margin (FY26)

p. 6
Aerospace: 388 crores revenue (21% growth) with 17.3% EBITDA margin.

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Defense revenue: 379 crores (25% growth), 22.9% EBITDA margin (FY26)

p. 6
Defense: 379 crores revenue (25% growth) with 22.9% EBITDA margin.

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

ESAI revenue: 136 crores (9% growth), 26.1% EBITDA margin (FY26)

p. 6
ESAI: 136 crores revenue (9% growth) with 26.1% EBITDA margin.

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

What management said it would do

A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.

FY27 consolidated revenue — 1,377 crores · FY27

stated firmly by Mr. Shashidhar S.K.

p. 6
Consolidated FY27 revenue is trending towards 1,377 crores (52% growth on the retained business base)

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

FY30 revenue target — 9,000 crores · FY2030

stated firmly by Dr. Sampath Ravinarayanan

p. 3
We set out on PAR 930 with a clear, non-negotiable target of 9,000 crores of revenue by FY2030

Dr. Sampath Ravinarayanan, page 3 of the filed PDF · View the filing

EBITDA margin improvement — 150 to 200 bps improvement · year-on-year

stated as an aspiration by Mr. Shashidhar S.K.

p. 6
What remains are the core verticals where the average EBITDA is already at 20% plus, and we aim for a 150 to 200 bps improvement year-on-year

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

EBITDA margin saturation — 25-27%

stated as an aspiration by Dr. Sampath Ravinarayanan

p. 7
We expect margins to saturate around 25-27%

Dr. Sampath Ravinarayanan, page 7 of the filed PDF · View the filing

Revenue recognition of deferred Q4 amount — 142 crores · Q1 and Q2 FY27

stated conditionally by Mr. Shashidhar S.K.

p. 5
The revenue has moved into FY27 visibility, with recognition expected across Q1 and Q2, subject to delivery, inspection, customer acceptance, and applicable criteria

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Cash release from land systems WIP — 120 to 140 crores · H1 FY27

stated conditionally by Mr. Shashidhar S.K.

p. 6
When these deliver, 120 to 140 crores of cash will be released

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Phase 2 disinvestment — H1 FY27

stated firmly by Dr. Sampath Ravinarayanan

p. 2
It will happen soon; the strategic rationale is unchanged, the process is active, and it remains a priority for H1 FY27

Dr. Sampath Ravinarayanan, page 2 of the filed PDF · View the filing

Akkodis transaction closure — Q2 FY27

stated firmly by Mr. Shashidhar S.K.

p. 5
The transaction is expected to close in Q2 FY27

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Total capex investment plan — 2,100 to 2,250 crores

stated firmly by Dr. Sampath Ravinarayanan

p. 7
The total investment plan is between 2,100 to 2,250 crores, which will be totally self-funded through the restructuring phases

Dr. Sampath Ravinarayanan, page 7 of the filed PDF · View the filing

Equity dilution / debt

stated firmly by Mr. Mukund Santhanam

p. 7
We have no plans for equity dilution or incremental long-term debt

Mr. Mukund Santhanam, page 7 of the filed PDF · View the filing

Q&A highlights

Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.

Management said the shift from design to manufacturing naturally produces a 10x to 20x jump in value and reaffirmed the target.

Answered by Dr. Sampath Ravinarayanan

Asked by Nikhil Chandak: Is the FY2030 target of 9,000 crores revenue still organically achievable given the 10x jump required?

p. 6
We are sticking to the 9,000-crore target; this is a foundational year.

Dr. Sampath Ravinarayanan, page 6 of the filed PDF · View the filing

Management said core verticals already run at 20%+ EBITDA and targeted further 150-200 bps improvement.

Answered by Mr. Shashidhar S.K.

Asked by Rohan Mehta: Are normalized EBITDA margins moving towards 20% for FY27, and can the order book be quantified?

p. 7
The non-core verticals were margin-dilutive.

Mr. Shashidhar S.K., page 7 of the filed PDF · View the filing

Management described the transaction as a slump sale with a one-year handhold period and a guaranteed plus earnout payment structure.

Answered by Mr. Shashidhar S.K.

Asked by Mayur Parkeria: Will the engineering division sale transfer immediately or run until June 2027, and what does the PAT target for FY30 imply?

p. 7
It is structured as a slump sale to the Akkodis entity in India.

Mr. Shashidhar S.K., page 7 of the filed PDF · View the filing

Management said Phase 2 disinvestment will fund further expansion and confirmed no dilution plans.

Answered by Dr. Sampath Ravinarayanan

Asked by Jatin Raghuwanshi: How is expansion funded beyond Akkodis cash given negative cash flow, and is there any equity dilution planned?

p. 6
Phase 2 of the disinvestment is coming very soon and will fund us totally for DAC, DAL, MAC, and our acquisitions.

Dr. Sampath Ravinarayanan, page 6 of the filed PDF · View the filing

Management described Xida's involvement in data centres and hyperscaler test equipment, and space bus/payload opportunities.

Answered by Dr. Sampath Ravinarayanan

Asked by Suman Gupta: What is the end product and total addressable market for space and hyperscaler businesses?

p. 7
Xida (formerly ESAI) is involved in data centres and test equipment for hyperscalers and semiconductor giants.

Dr. Sampath Ravinarayanan, page 7 of the filed PDF · View the filing

Management explained the manufacturing/serial-production model scales revenue automatically and expects margins to saturate at 25-27%.

Answered by Dr. Sampath Ravinarayanan

Asked by Disha: Would reaching 9,000 crores by FY30 require a 90% CAGR from FY28, and could higher EBITDA mean higher PAT than guided?

p. 7
We expect margins to saturate around 25-27%.

Dr. Sampath Ravinarayanan, page 7 of the filed PDF · View the filing

Management broke down capex across DAC, MAC, DAL and acquisitions, totaling a self-funded plan.

Answered by Dr. Sampath Ravinarayanan

Asked by Bala Subramanyan: What is the total capex program across facilities and acquisitions?

p. 7
DAC is 1,200 crores, MAC is 300 crores, and DAL is 120 crores (of which 100 crores is already spent).

Dr. Sampath Ravinarayanan, page 7 of the filed PDF · View the filing

Risks flagged

Supply chain disruption to a critical input material affected production timelines on a defense manufacturing program

p. 5
Supply chain disruption to a critical input material affected production timelines on land systems ordered for the Ministry of Defense.

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

A monopolistic hardware supplier redirected output to war-related priority programs, impacting production

p. 5
A monopolistic hardware supplier redirected output to war-related priority programs, impacting production.

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Deferment in an aerospace and defense contract arose from the divestment transaction transition

p. 5
An aerospace and defense contract where deferment arose directly from the divestment transaction transition.

Mr. Shashidhar S.K., page 5 of the filed PDF · View the filing

Inability to recognize deferred tax assets in a loss-making German entity raised the effective tax rate

p. 6
we could not recognize deferred tax assets in a loss-making German entity

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Negative operating cash flow driven by land systems work-in-progress

p. 6
Negative operating cash flow was driven entirely by 100 crores of land systems WIP, classified under "other assets".

Mr. Shashidhar S.K., page 6 of the filed PDF · View the filing

Government policy shifts towards Make in India required changes to proposals

p. 7
government policy shifts towards "Make in India" have required us to change our proposals

Dr. Sampath Ravinarayanan, page 7 of the filed PDF · View the filing

Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.